February was an intense and forward-looking month for iZafe Group. We continue to accelerate our growth and strengthen our market presence through strategic partnerships and expansion in multiple key markets. Despite seasonal variations, the number of active Dosell units increased by 9%, demonstrating continued strong demand and stable user growth. Spain successfully launched Dosell, while in Sweden, we rapidly expanded with new municipalities implementing our solution. At the same time, our establishment in the Netherlands progressed, and we look forward to further sales growth through upcoming trade fairs in both Spain and the Netherlands.

Spain: Official Launch and Initial Market Activities
After an intensive preparation phase, we have now officially launched Dosell in Spain! Spain has one of the largest healthcare markets in Europe, with over 22,000 pharmacies and an aging population driving demand for digital medication management solutions. This presents significant growth potential and an opportunity to establish Dosell as a leading solution in the market.
Our partner Ti-Medi has initiated marketing efforts by introducing the Savioo platform to all of its 1,500 pharmacies via email and through direct visits to pharmacies in multiple cities, including Barcelona, Girona, Lleida, Granollers, and Madrid. They currently produce dose sachets for 200,000 users, highlighting the significant potential for Dosell in the Spanish market.
To further strengthen our presence, we plan to gain media exposure in the near future, which will open new doors and increase awareness of Dosell in Spain. At the same time, Ti-Medi will be showcasing the Savioo concept along with Dosell at a major trade fair in Barcelona this March, providing additional visibility and opportunities to reach more industry players.

Sweden: Four New Municipalities in Operation and More on the Way
We launched Dosell in four new municipalities in February, while also conducting training sessions for two additional municipalities that plan to implement Dosell in March. Additionally, six new municipalities have expressed interest in adopting Dosell, with four of them already scheduling startup meetings in March and planning to activate their first units in April.
This represents a faster growth rate in terms of the number of municipalities than initially planned. Despite the positive development, we recognize that some challenges remain, particularly regarding the speed of implementation and initial volumes. While we have successfully introduced Dosell in multiple new municipalities in Sweden, the initial deployment is still relatively small-scale. To enhance scalability, we are focusing on improving training efforts for healthcare staff and simplifying the ordering process. However, municipalities plan to increase the number of units over time, reinforcing our strategy and our partners’ efforts to scale up Dosell’s implementation across Sweden.
Some of the feedback we have received from users and staff:

  • User: “I don’t have to think anymore! Finally, I get my medication at the right time, and when it lights up and beeps, I know it's time to take it.”
  • Healthcare Staff: “If a user hasn’t taken their medication, a simple phone call is enough to follow up—we don’t have to make a home visit.”
  • Healthcare Staff: “We chose Dosell as our medication dispenser because it is so simple and fits perfectly with all our municipality’s needs.”

The Netherlands: Stable Growth and Expanding Pipeline
Our market in the Netherlands continues to develop positively, with steadily increasing demand. Our partner's pipeline of new customers is growing, and we anticipate a high activation rate of Dosell units throughout the spring. Their investment in Dosell continues to yield results and is creating a stable platform for future expansion.
Additionally, our partner will be showcasing Dosell at a major trade fair in the Netherlands in April, which we believe will drive an even greater increase in sales.
We recommend following our partner’s journey in the Netherlands through their LinkedIn page, TCCN, for the latest updates and market developments.

Expansion and New Partnerships
Throughout February, we engaged in several exciting discussions with potential new partners in emerging markets. Moving forward, our strategy is to select partners with the best conditions for scaling Dosell on a larger scale. It is crucial to collaborate with organizations that understand how to implement digital technology and manage the necessary transformation processes required for successfully adopting Dosell.

We look forward to continued positive development in March and to building on the strong foundation we have established for our growth. We appreciate your engagement and look forward to sharing more progress in the upcoming updates!

iZafe Group's board member, Magnus Engman, acquired 200,000 B-shares in the company on February 26, at a total value of 52,459 SEK (0.262 SEK per share).

The acquisition is a clear signal of Magnus long-term confidence in iZafe's strategy and future potential. His total holding now amounts to 200,000 B-shares.

"I see great potential in iZafe's continued development and want to demonstrate my commitment by investing in the company. We have a clear growth strategy, and I am convinced that we are creating long-term value for our shareholders," says Magnus Engman.

iZafe Group AB ("iZafe Group") proudly announces the sales launch of Dosell in Spain through a strategic partnership with Ti-Medi, a leading player in pharmaceutical technology in Southern Europe. The launch and commercialization of Dosell, under the brand name Savioo Home, mark a significant milestone in the effort to enhance medication adherence and improve the quality of life for patients with chronic diseases.

Dosell has already established itself as an effective solution in countries such as Sweden and the Netherlands, helping users take the right medication at the right time. Through the partnership with Ti-Medi, Dosell will now be available to the Spanish market, integrating with Ti-Medi’s existing network of over 1,500 pharmacies that utilize their packaging technology for pre-dosed medications.
With Dosell, patients using Savioo Home will receive reminders to take their medication, and if they fail to do so on time, an automatic SMS alert will be sent to relatives or caregivers. This feature ensures a higher level of safety and security for both patients and their loved ones.

A Strategic Partnership for the Future
"We see tremendous potential in the Spanish market and are proud to launch Dosell through our collaboration with Ti-Medi. This is an important step in our international growth journey and our ambition to become a global leader in medication adherence," says Anders Segerström, CEO of iZafe Group.

"At Ti-Medi, we strive to provide technological solutions that simplify patients’ lives and optimize the work of healthcare professionals. Savioo Home not only automates medication management at home but also enhances security for patients, relatives, and pharmacists. This enables more precise monitoring and better adherence to treatment. We believe that the future of healthcare lies in digitalization and tools that increase safety, convenience, and trust – and Savioo Home is a major step in that direction," Says Rafa Tibau, Pharmacist and Co-founder of Ti-Medi

About Ti-Medi
Ti-Medi is a pioneer in pharmaceutical technology in Southern Europe, serving more than 1,500 pharmacies with advanced packaging and dosing solutions. The company’s mission is to enhance medication adherence and make healthcare more accessible and efficient. Read more at ti-medi.com

For more information about Savioo Home and how it can improve medication adherence and patient safety, visit the website savioo.com

2025 has started on a positive note for iZafe Group, with steady growth in Dosell and increasing demand across multiple markets. To provide better insights into our journey and progress, we are launching a monthly newsletter to share more frequent updates on developments behind the scenes.

If you are not yet receiving these updates via email, be sure to subscribe at the bottom of our website or through the link in our latest LinkedIn post. Follow us on LinkedIn for continuous updates.

Continuous Growth and Key Milestones
The number of billable Dosell units increased by 25% from December to January, a clear sign that our strategy and partnerships are driving demand.

Our growth is still from a smaller scale, but it is steadily increasing, bringing us closer to a key milestone of 1,000 active Dosell units in use. We expect to reach this soon, marking a significant step in our expansion.

Our business model is based on partners purchasing and stocking Dosell, ensuring cost coverage at the time of sale. The long-term value is generated when the units are activated, creating a recurring monthly revenue stream.

We have already shipped 2,500 Dosell units to our partners, who are experiencing strong demand and expect to activate them within 3–6 months. This increasing activation rate drives our revenue stream, creating a stable and scalable business model.

Sweden: Strong Momentum in VGR and More Municipalities Adopting Dosell
Dosell usage in Västra Götaland Region (VGR) has increased by 18% since December, and interest from municipalities continues to grow. We now have seven new municipalities scheduled for implementation in Q1, both within and outside VGR.

Our partners are actively driving Dosell through existing framework agreements, which accelerates deployment. To meet rising demand and support municipalities with implementation, we will host a webinar for VGR municipalities on March 6 in collaboration with ATEA.

At the MVTe trade fair, Dosell continued to generate strong interest from municipalities and private healthcare providers. Several follow-up meetings are scheduled in February.

Here are just a few comments from Swedish municipal staff, caregivers, and users about Dosell:

"We placed a Dosell with a user who was very skeptical at first. But after just a few days, she was thrilled that she could manage her medication independently while knowing that home care had full control in case she forgot."

"Our municipal staff was highly impressed after seeing Dosell presented. Compared to the larger, more complicated devices we previously used, Dosell will greatly simplify daily work."

"It is so easy to learn!"

"Using Dosell was the best decision we made. My father feels secure, and I receive alerts if anything deviates."

"When many other things started to become difficult due to memory loss, medication management continued to function thanks to Dosell."

Norway: Faster Implementation Through Partnerships
In Norway, we have partnered with Randstad to accelerate implementations and ensure optimal Dosell usage throughout contract periods.
In January, we conducted a comprehensive training session with Hepro, Careium AS, and Randstad to ensure a smooth rollout and equip their sales teams with the right tools for driving adoption.

Netherlands: Stable and Long-Term Growth
The Netherlands continues to be a key market with steady growth in Dosell adoption. Our partner has successfully integrated Dosell into its own platform, "Dispenze", which has been highly appreciated by customers. More organizations are now replacing competing solutions with Dosell.

A testament to our partner’s long-term commitment is their investment in a Dosell showroom, office, and branded delivery vehicles.

Follow TCCN on LinkedIn for regular insights and updates on how Dosell is used in the Netherlands.

Spain: Launch Around the Corner
Ti-medi has developed a comprehensive system and e-commerce solution to ensure a successful Dosell launch in Spain. The process has taken longer than expected, but we anticipate the launch happening in February.

Product Development: Improvements Drive Demand
Over the past year, we have released 13 software versions, and we are soon launching version 14, which includes significant enhancements.

Our goal has always been clear: Dosell should be simple and reliable for users, while we continuously improve refill processes, integrations, and the overall experience for caregivers and partners.

These ongoing improvements have been key to the growth we see today. Dosell is now more efficient than ever, which in turn drives increased demand.

Capital Raise and Focus on Profitability
We would also like to take this opportunity to thank our major shareholders for their support in the directed share issue of approximately SEK 9.2 million.

This capital injection strengthens our ability to accelerate growth while maintaining a clear focus on cost efficiency and achieving cash flow profitability.

We look forward to sharing more details in our upcoming quarterly report next week – stay tuned!

2024 has been a transformative year for iZafe Group, where we have laid a strong foundation for the future. We have multiplied our net revenue, delivered over 500 Dosell units to Spain, and are approaching 2,000 units in the Netherlands. The number of units that deliver the right medication at the right time daily has increased by approximately 500% compared to 2023, confirming that our solutions meet market needs and create real value.

Our partners have purchased hardware with the expectation of implementing these units within a relatively short period, which strengthens our business model of generating recurring monthly revenue.

The launch of Dosell 3.0 marks a milestone with improved functionality and integration. At the same time, we have changed production partners and built efficient production workflows, making us ready to scale up production to meet increasing demand and ensure high quality in every delivery. This work has laid a solid foundation for continued success.

Our innovative efforts have led to several new integrations, such as with Enovation UMO, and strong collaborations with partners like TCCN in the Netherlands and Ti Medi in Spain. These advancements reinforce Dosell as a global leader in health technology, providing solutions that enhance safety and independence for both users and healthcare staff. In Sweden, we have successfully implemented Dosell in numerous municipalities. Our solutions have been appreciated for their user-friendliness, safety, and ability to prevent medication errors. This has not only improved user independence but also streamlined the work of healthcare professionals. This success underscores Dosell's central role in digitalizing and optimizing healthcare at the municipal level.

Looking Ahead to 2025 With a solid foundation in place, we look forward to accelerating our growth. Our pipeline is strong, and we expect 2025 to build on the successes of this year. We plan to further expand Dosell’s presence while giving Pilloxa a central role in our portfolio. These initiatives will enable more innovative solutions and strengthen our position as a leader in health technology. We aim to continue creating value for our customers and shareholders through sustainable and profitable growth.

Thank You for Your Support I would like to extend my heartfelt thanks to our employees, partners, and shareholders. It is through your dedication and commitment that we can continue building a brighter future for healthcare and for iZafe Group. We look forward to 2025 with great ambition and strong confidence in our shared potential.

With warmth and appreciation,
Anders Segerström CEO, iZafe Group

iZafe Group AB announces that its product, Dosell, is now certified for integration with Enovation UMO, the monitoring solution for medical service centres. Enovation UMO is part of Enovation Platform, a leading platform for digital care and collaboration used in over 18 countries. This certification marks a significant milestone for iZafe and enables strategically important expansion in both established and new markets.

A Long-Awaited Solution for Dutch Partners
The certification has been highly anticipated by iZafe's partners in the Netherlands, where Enovation UMO is a well-established standard in healthcare. These partners have been eager to begin selling Dosell and can now leverage the seamless integration with the UMO platform. This ensures that Dosell not only complements but also enhances their offering by providing a comprehensive solution for medication management, alarms, and other digital healthcare services within the same platform.

"Creating a Unique Market Position"
"This certification is a critical milestone for iZafe and our partners, especially in the Dutch market, where interest in Dosell is substantial," says Anders Segerström, CEO of iZafe Group AB. "Dosell is specifically designed to be part of a healthcare technology ecosystem, and integrations like this not only simplify implementation but also improve the experience for both users and caregivers."

Benefits of an Integrated Ecosystem
By becoming certified on Enovation UMO, Dosell establishes a unique market position. Offering an integrated solution that handles medication management, alarms, and other care needs within a single platform meets the growing demand for comprehensive solutions in digital healthcare. This not only enhances iZafe's appeal to healthcare providers but also enables its partners to deliver a more competitive and value-driven offering to their customers.

Opening Doors to More Markets
Beyond the Netherlands, this integration also creates opportunities for iZafe to expand into other markets where Enovation UMO is established. With the platform’s presence in 18 countries, iZafe has a unique opportunity to strengthen its international presence and build relationships with new partners and customers.

A Step Forward for iZafe’s Growth Strategy
The certification is part of iZafe’s broader strategy to establish Dosell as a key component of the global healthcare technology landscape. By collaborating with established platforms like Enovation UMO, iZafe demonstrates its commitment to innovation and its ability to meet market demands for integrated and efficient healthcare solutions.
 
About Enovation Platform
Enovation UMO is part of the Enovation Platform: the leading platform for digital care and collaboration. With over 350 partners worldwide, the platform offers a wide variety of integrations. Enovation Platform uses open software, which connects seamlessly to care organisations' systems and those of their partner organisations. This way, the platform provides all the digital tools care professionals need to support patients or clients – whatever their needs.
https://enovationgroup.com/en/enovation-umo/

iZafe Group AB (publ) ("iZafe") announces today that it has received a new confirmed order for an additional 1,000 Dosell units from its exclusive distributor in the Netherlands, TCCN. This strategically important order has a value of approximately SEK 3 million. Deliveries will be split into two batches – 750 units in 2024 and the remaining 250 in the first half of 2025 – laying the foundation for stable licensing revenue of up to SEK 400,000 per month during 2025.

This order ensures that TCCN retains its exclusivity in the Dutch market, in accordance with previously communicated terms.

Once this order and previous ones are fully implemented, they are expected to generate recurring revenue of approximately SEK 400,000 per month in 2025. The order strengthens iZafe's cash flow and builds a long-term revenue model, clearly affirming Dosell's strong position as a leading solution in medication dispensing and a vital tool for the digitalization of the healthcare sector.
 
Since the beginning of the year, TCCN, which took over the exclusive distribution agreement for Dosell in the Netherlands, has established a dedicated office and showroom for Dosell in Assen. TCCN has successfully positioned Dosell in the rapidly growing Dutch medication dispensing market through partnerships with several leading players, including MobileCare.
 
"This order and the recurring revenue it generates demonstrate the enormous potential Dosell has to deliver both short-term results and long-term growth. We are impressed with TCCN’s work and view this development as a strategic milestone on our journey to making Dosell the leading solution for medication dispensing in Europe," says Anders Segerström, CEO of iZafe Group.
 
"The momentum for Dosell in the Dutch market is strong, both in the intramural and extramural market segments. With our gradual product introduction approach and focus on quality, we have built a solid foundation for TCCN’s new business unit. Our customers – healthcare providers for home care and intramural long-term care – appreciate the Dosell’s highly autonomous working, effortless deployment and low cost. We expect a strong growth going forward and this order enables us to meet the demand in the Dutch market during first half of 2025. " says Taeke Castelein, Managing Director of TCCN.
 
The Dutch market for medication dispensing solutions is in an expansive phase, where digital solutions are becoming increasingly central to improving patient safety and efficiency. Dosell meets these needs with its unique functionality that prevents double dosing and ensures correct medication intake. TCCN’s dedicated efforts have established Dosell as a strong player in this ecosystem, and continued implementation is expected to drive both market share and revenue growth.
 
For more information about TCCN, visit: https://tccn.eu.

About Dosell
The medicinal robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
In a Swedish report, it is estimated that 3,000 Swedes die annually from drug-related injuries and that 6–16 percent of hospital admissions are drug-related. The costs for drug-related injuries that can be avoided are estimated at SEK 5.6–24.6 billion per year.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing drug-related injuries.
Read more at www.dosell.com

iZafe Group's CFO, Marius Sandberg, has today acquired 177,793 B-shares in the company at a value of SEK 34,909 (SEK 0.196 per share).

The acquisition was completed today, November 14, bringing Marius Sandberg's total shareholding in iZafe to 177,983 B-shares.
"As the new CFO, I see the potential that exists in iZafe, and with this share purchase, I am demonstrating my confidence in the company’s future. I look forward to being part of iZafe’s growth journey and to continue working towards creating value for our shareholders and contributing to the company’s long-term success," says Marius Sandberg, CFO of iZafe Group.

iZafe Group AB (“iZafe Group”) is thrilled to announce the grand launch of Dosell in collaboration with Ti Medi, taking place in Granada on October 22-23. The event marks a pivotal moment as Ti Medi introduces its innovative concept, combining the Savioo Website and Dosell medication dispenser, to the Spanish market. Attendees at the event include 150 Ti Medi's customers, who will gain exclusive insights into Dosell and its transformative impact on medication adherence. Ti Medi's extensive network includes around 1,400 pharmacies, which significantly expanding the potential reach and impact of this innovative concept.

This launch paves the way for Dosell to become commercially available in Spain, with the first active units expected to be operational shortly. The collaboration between iZafe Group and Ti Medi represents a breakthrough in addressing the critical need for efficient and reliable medication management. The event highlights the tireless efforts and commitment of both teams in bringing this solution to life.
 
“We are incredibly proud to see the result of months of hard work and dedication as Dosell is now launched in Spain. This is a significant milestone, not only for iZafe Group but for the entire healthcare sector in Spain. Dosell will make a substantial difference in patients’ lives by simplifying their medication management. The launch also serves as strong proof of our successful partnership with Ti Medi, and we look forward to following Dosell’s impact on the Spanish market,” says Anders Segerström, CEO of iZafe Group.
 
The event in Granada serves as the official introduction of Dosell to Ti Medi's extensive network of clients, showcasing its potential to revolutionize medication adherence through an integrated system. The comprehensive approach, which includes Ti Medi's packaging technology alongside Dosell, empowers pharmacies to monitor patients’ adherence with unprecedented efficiency.
 
Marc Tarruell Tibau, CEO of Ti Medi, adds, “Bringing Dosell into our solution portfolio is a game changer. Our customers will now be able to offer an all-in-one package that significantly enhances medication management. This integration is a key step forward in improving adherence and, ultimately, patient outcomes.”
 
With Dosell now available on the Spanish market, iZafe Group is poised to continue expanding its footprint in Europe, with Spain set to become one of the key markets for the company's innovative healthcare solutions.

iZafe Group AB ("iZafe Group") today announces a strategic partnership with Randstad, a global leader in healthcare personnel services, to launch a new initiative in Norway. This collaboration aims to ensure the long-term and effective implementation of Dosell's medication dispensers across Norwegian municipalities by providing the right personnel with comprehensive training and ongoing support.

As part of our relaunch in Norway, we recognize that the most critical factor for success is effective implementation. Randstad will play a central role in managing significant parts of this implementation, regardless of which partner in Norway sells Dosell.

With the increasing demand for efficient medication management in healthcare systems, Dosell's partnership with Randstad combines technological innovation with human expertise. Randstad's strong presence in nearly all municipalities in Norway allows for tailored staffing solutions and professional development programs, ensuring that healthcare professionals are fully trained to use Dosell's cutting-edge medicine dispenser. The initiative aims to enhance patient safety and optimize medication management throughout Norway's healthcare sector.

"We are very excited to launch this partnership with Randstad in Norway, a country where we see great potential for improving medication management through our technology," says Anders Segerström, CEO of iZafe Group. "By collaborating with Randstad, which has an extensive network and deep understanding of the local healthcare landscape, we can ensure that our medicine dispenser is implemented effectively and sustainably across Norwegian municipalities. This partnership is about combining the best technology with the right people to deliver long-term, high-quality healthcare solutions."

Per Arne Lien, Manager of Health Technology at Randstad, commented, "Our extensive presence in the majority of the municipalities in Norway allows us to uniquely understand the local needs and challenges of healthcare providers. Partnering with Dosell enables us to support Norwegian municipalities with experienced, well-trained professionals who can ensure the successful integration and long-term use of Dosell's medicine dispenser. Together, we are committed to advancing healthcare quality and patient outcomes in Norway through innovation and expertise."

The partnership will begin with a pilot program across several municipalities in Norway, focusing on delivering comprehensive training for healthcare professionals and providing continuous support and advisory services. This approach ensures that Dosell's technology is not only effectively implemented but also continuously optimized to meet the evolving needs of healthcare providers and their patients.

About Dosell
The medicinal robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
In a Swedish report, it is estimated that 3,000 Swedes die annually from drug-related injuries and that 6–16 percent of hospital admissions are drug-related. The costs for drug-related injuries that can be avoided are estimated at SEK 5.6–24.6 billion per year.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing drug-related injuries.
Read more at www.dosell.se

About Randstad
Randstad is a global leader in HR services, specializing in staffing, talent management, and workforce solutions. In Norway, Randstad has a significant presence across nearly all municipalities, providing skilled professionals to support local healthcare services and other sectors.

Webbdesign av Comlog Webbyrå Stockholm